Trials / Completed
CompletedNCT04509947
A Study of Ad26.COV2.S in Adults (COVID-19)
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 250 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) at 2-dose levels, as 2-dose schedule in healthy participants aged greater than or equal to 20 to less than or equal to 55 years and greater than or equal to 65 years in good health with or without stable underlying conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ad26.COV2.S | Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels. |
| BIOLOGICAL | Placebo | Placebo will be administered as IM injection. |
Timeline
- Start date
- 2020-08-11
- Primary completion
- 2021-02-22
- Completion
- 2021-11-16
- First posted
- 2020-08-12
- Last updated
- 2021-11-24
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04509947. Inclusion in this directory is not an endorsement.